Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients

Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...